In their meta-analysis, Serritella and Shenoy [77] found that ipilimumab + nivolumab compared with nivolumab alone did not provide tangible or meaningful improvement in OS and PFS for patients with NSCLC (squamous), NSCLC (PDL1 ≥ 1%), SCLC, pleural mesothelioma, urothelial carcinoma, esophageal carcinoma, sarcoma, or glioblastoma multiforme. This evidence concerns the gene CD274 and non-small cell lung carcinoma.